戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 thioate oligodeoxynucleotides (Sd, potential anti-HIV drugs).
2 osis, HCV genotype, and exposure to specific anti-HIV drugs.
3 m and to develop resistance to the available anti-HIV drugs.
4 RT) is a major target for currently approved anti-HIV drugs.
5 ing minocycline in the class of anticellular anti-HIV drugs.
6 nfluenced by slope and varies by >8 logs for anti-HIV drugs.
7 '-dideoxynucleosides (d4Ns) are FDA-approved anti-HIV drugs.
8 e transcriptase inhibitors, a major class of anti-HIV drugs.
9  for development of an entirely new class of anti-HIV drugs.
10 y serve as an important target for designing anti-HIV drugs.
11 nd has great potential as a novel target for anti-HIV drugs.
12 ly being targeted for the development of new anti-HIV drugs.
13 ereby contribute to the clinical efficacy of anti-HIV drugs.
14 be used in the development of more effective anti-HIV drugs.
15 cation of a new class of orally bioavailable anti-HIV drugs.
16  for the intradermal delivery of hydrophobic anti-HIV drugs.
17  a promising scaffold for the development of anti-HIV drugs.
18                                              Anti-HIV drugs, alone or in combination, did not materia
19                        Efavirenz (EFV) is an anti-HIV drug, and cytochrome P450 46A1 (CYP46A1) is the
20 sponsible for the resistance of HTLV-1 PR to anti-HIV drugs are identified.
21                                   The use of anti-HIV drugs as cancer treatments is not new.
22 explain the development of resistance to the anti-HIV drug AZT.
23 rovide a novel target for the development of anti-HIV drugs based on the concept of trapping a nonnat
24 rk investigating the lymphatic uptake of two anti-HIV drugs: cabotegravir (CAB) and rilpivirine (RPV)
25         In this article, we characterize the anti-HIV drug candidate 3-O-(3',3'-dimethylsuccinyl) bet
26 fected people.IMPORTANCE A growing number of anti-HIV drug combinations are effective in suppressing
27 e inhibitors (NRTIs), the most commonly used anti-HIV drugs, compete against cellular dNTPs for incor
28  Griffithsin, and to T-20 and maraviroc, two anti-HIV drugs currently in clinical use.
29 om the Data-Collection on Adverse Effects of Anti-HIV Drugs (D:A:D) and International Cohort Consorti
30 rom the Data Collection on Adverse events of Anti-HIV Drugs (D:A:D) cohort between January 1999 throu
31 nd the data-collection on adverse effects of anti-HIV drugs (D:A:D) risk score.
32  on the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) score, which summarizes clinical
33 rom the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study contributed 309803 person-y
34 s: the Data Collection on Adverse Effects of Anti-HIV Drugs (D:A:D) study equation.
35     The Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study has developed predictive ri
36 rom the Data collection on Adverse events of anti-HIV Drugs (D:A:D) study were followed up from March
37  in the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study were followed up until the
38 rom the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study with >/=3 estimated glomeru
39     The Data Collection on Adverse Events of Anti-HIV Drugs (DAD) study has reported an increased ris
40                                              Anti-HIV drug (Dapivirine, DPV), anti-herpes drug (Prite
41 e are at least three high priority goals for anti-HIV drug delivery (DD) research: (1) to prevent new
42  therefore represents a promising target for anti-HIV drug design.
43 iption, it represents a promising target for anti-HIV drug design.
44 n and represents a very promising target for anti-HIV drug design.
45 on cycle of HIV and has been a key target of anti-HIV drug development efforts.
46 n urgent need for new ways of thinking about anti-HIV drug development, and accordingly novel viral a
47 complex could become an important target for anti-HIV drug development, where a drug could exert its
48 V-1 cell entry has long been a major goal of anti-HIV drug development.
49 d from this study may be important for novel anti-HIV drug development.
50 s of Nef signaling and potential targets for anti-HIV drug discovery.
51 ost protein complex as a rational target for anti-HIV drug discovery.
52                Previously, we found that the anti-HIV drug efavirenz (EFV) can pharmacologically acti
53                                          The anti-HIV drug efavirenz activates CYP46A1 at low drug le
54 validated for HIV by the FDA approval of the anti-HIV drug enfuvirtide.
55  more lipophilic than the currently approved anti-HIV drugs for better blood-brain barrier penetratio
56                  Although a number of useful anti-HIV drugs have been approved for use in patients, t
57                                        Thus, anti-HIV drugs have little or no activity against P. car
58 V-infection, Coc exposure and treatment with anti-HIV drug i.e., Tef, and Coc antagonist i.e., RA.
59 -dideoxyadenosine (F-ddA, lodenosine), a new anti-HIV drug, in human lymphocytes by HPLC using fluore
60 ading capacity of hydrophobic anticancer and anti-HIV drugs, indicating promising applications in HIV
61 eficiency virus (HIV) leading to escape from anti-HIV drugs is the greatest challenge to the treatmen
62 egion, is the first member of a new class of anti-HIV drugs known as HIV fusion inhibitors.
63 p synthesis of the main fragment of Gilead's anti-HIV drug lenacapavir is described.
64 ion of viral replication achieved by current anti-HIV drugs, many patients fail treatment, often with
65 ancer drugs with multiple effects, and other anti-HIV drugs might hold similar promise.
66  deplete host-cell dTTP, unlike conventional anti-HIV drug monotherapy directed solely at viral enzym
67  Cytochrome P450-dependent metabolism of the anti-HIV drug nevirapine (NVP) to 12-hydroxy-NVP (12-OHN
68 effectively targeted by a combined use of an anti-HIV drug (NVR) and a metabolic inhibitor (ML355).
69 ports of the susceptibility of P. carinii to anti-HIV drugs on the basis of in vitro testing only.
70                                              Anti-HIV drugs or virus-neutralizing monoclonal antibodi
71 vir increases plasma concentrations of other anti-HIV drugs oxidized by CYP3A4 thereby improving clin
72 wledge accumulated during the development of anti-HIV drugs, particularly in overcoming drug resistan
73 he IN, which is a new target in the field of anti-HIV drug research.
74 ations made during the Collaborative HIV and Anti-HIV Drug Resistance Network (CHAIN)/WHO meeting (Oc
75 nhibitor ritonavir as a pharmacoenhancer for anti-HIV drugs revolutionized the treatment of HIV infec
76  in the Data Collection on Adverse Events of Anti-HIV Drugs study without HCV or HBV coinfection were
77 RP4) functions as a cellular efflux pump for anti-HIV drugs, such as 9-(2-phoshoenylmethoxyethyl) ade
78 -dimensional nanomaterials and the design of anti-HIV drugs targeting (dis)assembly and biocompatible
79 ort and provide opportunities for developing anti-HIV drugs targeting specific RRE conformations.
80  briefly discuss several actin pathway-based anti-HIV drugs that are currently in development or test
81          Thus, dCA defines a unique class of anti-HIV drugs that may inhibit viral production from st
82 ut the source of the sequence sample and the anti-HIV drug treatment history of the individual from w
83 f anemia should be considered when examining anti-HIV drug treatment regimens in HIV-1C-predominant a
84                                       Twelve anti-HIV drugs were analyzed for their effects against r
85 the nucleoside inhibitors used clinically as anti-HIV drugs which target HIV-1 reverse transcriptase
86 cs were regulated by cognate nucleotides and anti-HIV drugs, which stabilized and destabilized the po
87 control point to the need for new classes of anti-HIV drugs with different modes of action.
88                                              Anti-HIV drugs work; so far drug therapy has saved more